Fraser Todd A, Corke Charlie F, Mohajeri Morteza, Stevenson Lisa, Campbell Philip J
Department of Intensive Care Medicine, The Geelong Hospital, Geelong, VIC, Australia.
Crit Care Resusc. 2006 Jun;8(2):141-5.
To review the frequency of use, possible efficacy and safety profile of Prothrombinex-HT (CSL Bioplasma, Melbourne, VIC) in treatment of patients with microvascular bleeding refractory to standard measures after cardiothoracic surgery.
A retrospective chart review was performed of 60 consecutive cardiothoracic surgical patients who received Prothrombinex-HT between February and August 2003. Data collected included baseline demographic information, nature and complexity of surgery, preoperative medications, baseline haematological parameters and evidence of clinically significant prothrombotic complications. Consumption of blood products, haematological parameters and mediastinal bleeding rates before and after administration of Prothrombinex-HT were documented in 22 patients who received Prothrombinex-HT in the ICU.
No major prothrombotic complications were noted in the series of 60 patients. Two patients had superficial thrombophlebitis. Blood product consumption and haematological parameters were markedly reduced after administering Prothrombinex-HT.
Use of Prothrombinex-HT was not associated with significant prothrombotic complications. Limited evidence of its efficacy suggests that it should be further evaluated in the setting of cardiothoracic surgery.
回顾凝血酶原复合物-HT（CSL生物血浆公司，墨尔本，维多利亚州）用于治疗心胸外科手术后对标准措施难治的微血管出血患者的使用频率、可能的疗效和安全性。
对2003年2月至8月期间连续60例接受凝血酶原复合物-HT治疗的心胸外科手术患者进行回顾性病历审查。收集的数据包括基线人口统计学信息、手术性质和复杂性、术前用药、基线血液学参数以及临床上显著的血栓形成并发症的证据。在重症监护病房接受凝血酶原复合物-HT治疗的22例患者中记录了使用凝血酶原复合物-HT前后的血液制品消耗、血液学参数和纵隔出血率。
在这60例患者中未发现严重的血栓形成并发症。2例患者出现浅表性血栓性静脉炎。使用凝血酶原复合物-HT后，血液制品消耗和血液学参数明显降低。
使用凝血酶原复合物-HT未出现显著的血栓形成并发症。其疗效的有限证据表明，应在心胸外科手术中对其进行进一步评估。
